Form 4: Entera Bio Director Receives Stock and Options in Lieu of Cash Compensation
SEC Form 4
A director of Entera Bio Ltd. received shares and stock options as compensation for services and as part of an annual grant.
Summary
- Haya Taitel, a director at Entera Bio Ltd., received 6,922 ordinary shares as compensation for services rendered in the fourth quarter of 2024.
- These shares were awarded in lieu of cash fees.
- Additionally, Taitel received 28,509 stock options as part of the Board's annual grant to directors.
- The stock options have an exercise price of $2.28 and vest ratably over one year, starting January 1, 2025.
- The options expire on January 15, 2035.
Sentiment
Score: 7
Explanation: The document reflects standard corporate governance practices and director compensation, which is generally viewed positively. There are no indications of negative sentiment.
Positives
- The director's compensation in the form of shares aligns their interests with the company's performance.
- The vesting schedule of the options encourages long-term commitment from the director.
Industry Context
It is common practice for companies to compensate directors with a mix of cash, shares, and stock options to align their interests with shareholders and incentivize long-term value creation.
Comparison to Industry Standards
- Many biotech companies use stock options and share grants as part of director compensation packages.
- The vesting schedule of one year is a common practice to ensure directors are incentivized to stay with the company.
- The exercise price of $2.28 is a standard feature of stock options, and the 10 year expiry is also common.
Stakeholder Impact
- Shareholders may view the share and option grants as a positive sign of aligning director interests with company performance.
- The director is incentivized to contribute to the company's success due to the vesting schedule of the options.
Key Dates
| Date | Description |
|---|---|
| 01/15/2025 | Date of the share and stock option grant. |
| 01/15/2035 | Expiration date of the stock options. |
| 01/17/2025 | Date of the filing of the form. |
Keywords
Entera Bio, Director Compensation, Stock Options, Share Award, Corporate Governance, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.